LigaChem Biosciences
LigaChem Biosciences Inc (formerly LegoChem Biosciences) is a South Korean clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of next-generation antibody-drug conjugates (ADCs) and targeted therapeutics for the treatment of cancer and infectious diseases, utilizing its proprietary ConjuAll ADC technology platform. The company designs novel therapeutic molecules engineered to deliver cytotoxic agents precisely to cancer cells while minimizing systemic toxicity. Its core business operations encompass biopharmaceutical research, ADC technology platform development, clinical trial execution, and licensing partnerships with major global pharmaceutical corporations. As a clinical-stage biotechnology enterprise, the company generates revenue primarily through technology licensing fees, milestone payments, and collaborative research agreements. LigaChem Biosciences holds a pioneering global market position in antibody-drug conjugate engineering and targeted cancer therapeutics. The company is headquartered in Daejeon, South Korea, and its shares trade on the KOSDAQ market.
4 of the funds FundTelligence covers report a position in LigaChem Biosciences.
- Legal name
- LigaChem Biosciences Inc
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 4
Funds holding LigaChem Biosciences
- JPM Korea Equity Fund — JPM · 0.25 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)